Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors

Oncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase fusion proteins. Nevertheless, the optimal path...

Full description

Saved in:
Bibliographic Details
Main Authors: Mariana Petaccia de Macedo (Author), Ellen Caroline Toledo Nascimento (Author), Fernando Augusto Soares (Author), Fernando Costa Santini (Author), Felipe D'Almeida Costa (Author), Isabela Werneck da Cunha (Author), Rodrigo Ramella Munhoz (Author), Pedro De Marchi (Author), Thiago William Carnier Jorge (Author), Kátia Ramos Moreira Leite (Author)
Format: Book
Published: SAGE Publishing, 2023-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c608b264cfcf42a8b61f08fbb8e9d2c7
042 |a dc 
100 1 0 |a Mariana Petaccia de Macedo  |e author 
700 1 0 |a Ellen Caroline Toledo Nascimento  |e author 
700 1 0 |a Fernando Augusto Soares  |e author 
700 1 0 |a Fernando Costa Santini  |e author 
700 1 0 |a Felipe D'Almeida Costa  |e author 
700 1 0 |a Isabela Werneck da Cunha  |e author 
700 1 0 |a Rodrigo Ramella Munhoz  |e author 
700 1 0 |a Pedro De Marchi  |e author 
700 1 0 |a Thiago William Carnier Jorge  |e author 
700 1 0 |a Kátia Ramos Moreira Leite  |e author 
245 0 0 |a Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors 
260 |b SAGE Publishing,   |c 2023-09-01T00:00:00Z. 
500 |a 2632-010X 
500 |a 10.1177/2632010X231197080 
520 |a Oncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase fusion proteins. Nevertheless, the optimal pathways and diagnostic platforms for this biomarker's screening and genomic profiling have not been defined and remain a subject of debate. A panel of national experts in molecular cancer diagnosis and treatment was convened by videoconference and suggested topics to be addressed in the literature review. The authors proposed a testing algorithm for oncogenic neurotrophic tropomyosin receptor kinase gene fusion screening and diagnosis for the Brazilian health system. This review aims to discuss the latest literature evidence and international consensus on neurotrophic tropomyosin receptor kinase gene fusion diagnosis to devise clinical guidelines for testing this biomarker. We propose an algorithm in which testing for this biomarker should be requested to diagnose advanced metastatic tumors without known driver mutations. In this strategy, Immunohistochemistry should be used as a screening test followed by confirmatory next-generation sequencing in immunohistochemistry-positive cases. 
546 |a EN 
690 |a Pathology 
690 |a RB1-214 
655 7 |a article  |2 local 
786 0 |n Clinical Pathology, Vol 16 (2023) 
787 0 |n https://doi.org/10.1177/2632010X231197080 
787 0 |n https://doaj.org/toc/2632-010X 
856 4 1 |u https://doaj.org/article/c608b264cfcf42a8b61f08fbb8e9d2c7  |z Connect to this object online.